Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

AIM: To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS: Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunod...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :World J Hepatol
Главные авторы: Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Формат: Artigo
Язык:Inglês
Опубликовано: Baishideng Publishing Group Inc 2017
Предметы:
Observational Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395804/
https://ncbi.nlm.nih.gov/pubmed/28469811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v9.i11.551
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы